Exousia Bio EBIT

Exousia Bio (LMMY) currently reports a EBIT of $-420K as of February 2026. That compares with $-33K in the prior-year period — down 1151.7% year over year. That is below the sector sector average of $2.6T. Use the charts on this page to explore Exousia Bio's EBIT history and peer comparisons.

Exousia Bio's EBIT decreased from $-33K to $-420K — a 1151.7% year-over-year decrease (period ending February 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Exousia Bio's EBIT of $-420K is lower than the its sector sector average of $2.6T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Exousia Bio reported $-420K in EBIT as of February 2026. That compares with $-33K in the prior-year period — down 1151.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-420K, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $2.6T. From there, open related valuation or income-statement pages for Exousia Bio, and consider following LMMY for alerts when major investors trade the stock.